Development of solid drug nanoparticle dispersions for pulmonary delivery of niclosamide and nitazoxanide via vibrating mesh nebulisation†

Catherine Unsworth, Andrew B. Dwyer, Alison C. Savage, James J. Hobson, Jonathan Massam, Tom O. McDonald, Paul Curley, Andrew Owen, Andrew O'Sullivan, Ronan MacLoughlin and Steve P. Rannard
{"title":"Development of solid drug nanoparticle dispersions for pulmonary delivery of niclosamide and nitazoxanide via vibrating mesh nebulisation†","authors":"Catherine Unsworth, Andrew B. Dwyer, Alison C. Savage, James J. Hobson, Jonathan Massam, Tom O. McDonald, Paul Curley, Andrew Owen, Andrew O'Sullivan, Ronan MacLoughlin and Steve P. Rannard","doi":"10.1039/D5PM00006H","DOIUrl":null,"url":null,"abstract":"<p >The optimum delivery of very poorly soluble drug compounds is challenging, especially if targeting of disease sites is required. Delivery to the lung is hampered by a range of physiological issues, and inhalation may be the most appropriate route. When breathing is compromised by infection or poor lung capacity, nebulisation may enable therapeutics to be carried deep into the respiratory tract. Here we report the development of nebulised aqueous formulations of two highly water-insoluble drugs with demonstrated anti-SARS-CoV-2 activity and evaluate their pulmonary delivery using <em>in vitro</em> models that include the breathing patterns of children and COVID-19 infected adults.</p>","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 3","pages":" 517-526"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2025/pm/d5pm00006h?page=search","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RSC Pharmaceutics","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/pm/d5pm00006h","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The optimum delivery of very poorly soluble drug compounds is challenging, especially if targeting of disease sites is required. Delivery to the lung is hampered by a range of physiological issues, and inhalation may be the most appropriate route. When breathing is compromised by infection or poor lung capacity, nebulisation may enable therapeutics to be carried deep into the respiratory tract. Here we report the development of nebulised aqueous formulations of two highly water-insoluble drugs with demonstrated anti-SARS-CoV-2 activity and evaluate their pulmonary delivery using in vitro models that include the breathing patterns of children and COVID-19 infected adults.

纳米固体药物分散体的研制,用于通过振动网雾化给药奈洛沙胺和硝唑昔尼特肺输送
极难溶性药物化合物的最佳递送是具有挑战性的,特别是如果需要靶向疾病部位。输送到肺部受到一系列生理问题的阻碍,吸入可能是最合适的途径。当呼吸因感染或肺活量不足而受到损害时,雾化可使治疗药物深入呼吸道。在这里,我们报告了两种具有抗sars - cov -2活性的高度水不溶性药物的雾化水制剂的开发,并使用体外模型(包括儿童和COVID-19感染成人的呼吸模式)评估了它们的肺输送。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信